NA
ARQT icon

Navellier & Associates’s Arcutis Biotherapeutics ARQT Stock Holding History

Navellier & Associates’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516K Buy
19,696
+5,943
+43% +$138K 0.04% 243
2026
Q1 		$324K Buy
+13,753
New +$351K 0.03% 274

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Navellier & Associates's ARQT Position: Q2 2026 in Review

Navellier & Associates increased its Arcutis Biotherapeutics (ARQT) stake by 43% in Q2 2026, buying an estimated $138K and bringing the position to 19,696 shares worth $516K. The position accounts for 0.04% of the portfolio, ranked #243.

Navellier & Associates first reported a position in ARQT in Q1 2026 and has held it in 2 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Navellier & Associates held 19,696 shares of Arcutis Biotherapeutics worth $516K as of Q2 2026.
  • Navellier & Associates bought 5,943 Arcutis Biotherapeutics shares in Q2 2026, an estimated $138K.
  • Arcutis Biotherapeutics made up 0.04% of Navellier & Associates's portfolio in Q2 2026, its #243 holding.
  • Navellier & Associates first reported a position in Arcutis Biotherapeutics in Q1 2026 and has held it in 2 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Navellier & Associates's 13F filing for Q2 2026, filed 4 Aug 2026.